Episode Details
Back to Episodes
Skyhawk's Early Huntington Signal Faces a Bigger Test & Sling Raises $123M
Season 1
Published 1 day, 23 hours ago
Description
Skyhawk's early SKY-0515 Huntington's signal faces randomized confirmation, while Sling's $123M financing advances oral linsitinib for thyroid eye disease. Alex and Maya examine Novartis's Sironax option and Cogent's bezuclastinib review timetable. They also cover FDA review patterns, Bausch + Lomb's warning letter, and Gilead and PAHO's lenacapavir access agreement. The briefing follows what these clinical, financial and regulatory developments mean, with the evidence limits that matter.
Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.